Rafferty Asset Management, LLC Alx Oncology Holdings Inc Transaction History

Rafferty Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$5.89 - $19.46 $923,999 - $3.05 Million	-156,876 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$13.65 - $22.06 $681,080 - $1.1 Million	49,896 Added 46.64%	156,876 $2.65 Million
Q4 2021 Feb 10, 2022	BUY	$21.49 - $74.4 $2.3 Million - $7.96 Million	106,980 New	106,980 $2.3 Million
Q3 2021 Nov 10, 2021	SELL	$52.51 - $80.91 $2.3 Million - $3.54 Million	-43,721 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$52.2 - $75.23 $28,083 - $40,473	538 Added 1.25%	43,721 $2.39 Million
Q1 2021 May 10, 2021	BUY	$62.84 - $87.68 $2.51 Million - $3.51 Million	39,982 Added 1249.05%	43,183 $3.18 Million
Q4 2020 Feb 10, 2021	BUY	$34.11 - $112.26 $109,186 - $359,344	3,201 New	3,201 $276,000

101

39.7M

134K

17.4K

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $72.1M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.